Log In
BCIQ
Print this Print this
 

AKN-083

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionSmall molecule non-bile acid farnesoid X receptor (FXR; NR1H4) agonist
Molecular Target Farnesoid X receptor (FXR) (NR1H4)
Mechanism of ActionFarnesoid X receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/20/2016

Undisclosed

$50.0M

Undisclosed

Get a free BioCentury trial today